Evidence map›Paper›PMID 37253975›Full record

ArticleProstate cancer and prostatic diseases2023

Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.

Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, Susanne Krege, Jürgen Gschwend, Heidrun Rexer, Kerstin Junker, Roger Zillmann, Christoph Rüssel, Eva Hellmis and 11 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Carsten-Henning OhlmannDepartment of Urology, Saarland University Medical Center, Homburg/Saar, Germany. carsten-henning.ohlmann@bn.johanniter-kliniken.de.ORCID http://orcid.org/0000-0003-1562-5364
Michelle JäschkeDepartment of Urology, Saarland University Medical Center, Homburg/Saar, Germany.
Peter Jaehnigpj statistics, Berlin, Germany.
Susanne KregeDepartment of Urology, Evangelische Kliniken Essen Mitte, Essen, Germany.
Jürgen GschwendDepartment of Urology, Klinikum Rechts der Isar, Technical University Munich, Munich, Germany.
Heidrun RexerMeckevidence, Schwarz, Germany.
Kerstin JunkerDepartment of Urology, Saarland University Medical Center, Homburg/Saar, Germany.
Roger ZillmannUrologie Pankow, Berlin, Germany.
Christoph RüsselUrologie Borken, Borken, Germany.
Eva HellmisUrologicum-Duisburg Fachärztesozietät, Duisburg, Germany.
Henrik SuttmannUrologikum Hamburg MVW, Hamburg, Germany.
Martin JanssenDepartment of Urology, Saarland University Medical Center, Homburg/Saar, Germany.
Jan MarinUrologie Kempen, Münster, Germany.
Andreas HübnerZentrum für Onkologie und Urologie, Rostock, Germany.
Michael MathersPandamed, Remscheid, Germany.
Jochen GleißnerUro-Gyn-Praxis Am Wall, Wuppertal, Germany.
Michael SchefflerUrologische Gemeinschaftspraxis, Zwickau, Germany.
Susan FeyerabendStudienpraxis Urologie, Nürtingen, Germany.
Jens TelleUrologische Praxisgemeinschaft, Wolfsburg, Germany.
Jörg KlierUrologische Partnerschaft, Köln, Germany.
Michael StöckleDepartment of Urology, Saarland University Medical Center, Homburg/Saar, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37253975
PMCPMC10638078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.